Previous Article | Next Article ![]()
Molecular and Cellular Biology, April 2006, p. 3282-3294, Vol. 26, No. 8
0270-7306/06/$08.00+0 doi:10.1128/MCB.26.8.3282-3294.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Molecular Chaperone Biology/Radiobiology Program, Medical College of Georgia, 1120 15th St., CB2803, Augusta, Georgia 30912
Received 1 August 2005/ Returned for modification 30 September 2005/ Accepted 23 January 2006
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
The heat shock factor Hsf4 possesses alternative splice variants leading to generation of two isoforms: Hsf4a that has transcriptional repressor activity and Hsf4b that has transcriptional activator properties (35, 41). Human cell lines expressing exogenous Hsf4a exhibit lower levels of basal and inducible expression of Hsp-90, -70, and -25 (35, 41, 51). In addition, in an in vitro reconstitution system, the mechanism underlying Hsf4a transcriptional repression appears to be through its interaction with the basal transcription factor TFIIF, leading to inhibition of proper assembly of basal transcription machinery (17). In contrast, the Hsf4b isoform is a relatively weak transcriptional activator compared to Hsf1, although Hsf4b can complement survival defects of Saccharomyces cerevisiae cells that lack Hsf (41). Interestingly, missense mutations in the DNA binding domain of hsf4 gene have been detected in humans with Marner and lamellar cataracts (7). Similarly, targeted disruption of the hsf4 gene in mice results in lens degeneration and cataract development early during postnatal development (18, 33). Hsf4 binding to the heat shock element (HSE) can be detected in the lens between postnatal day 1 to 5, and it remains active into adulthood. The results suggest that Hsf4b plays a critical role in the lens fiber cell maturation. While the developmental role of Hsf4 is becoming clear, the mode of Hsf4 regulation of transcription is not yet understood.
To examine the molecular mechanisms controlling the transcriptional activity of Hsf4b, we used Hsf4b as a bait in a yeast two-hybrid screening system and have identified a novel dual-specificity tyrosine phosphatase (genomic designation DUSP26) that interacts with Hsf4b. Dual-specificity tyrosine phosphatases (DSPs) are similar to tyrosine phosphatases by possessing the tyrosine phosphatase signature motif (I/V)HCXAGXGR(S/T) involved in their catalytic activity (4, 25). Thus far, many dual-specificity tyrosine phosphatases have been identified, and they recognize T-X-Y motifs that are phosphorylated by MEK1/2, MKK3/6, or MKK7 located upstream of mitogen-activated protein (MAP) kinases, ERK1/2, JNK, and the p38 protein kinases (
, ß,
,
) (8, 25). The human genome encodes 38 dual-specificity tyrosine phosphatases. Among them there are 11 MAP kinase phosphatases, 17 atypical dual-specificity phosphatases, 4 PRL phosphatases, 3 Cdc14 phosphatases, and 3 Cdc25 phosphatases (16). A partial list of the dual-specificity tyrosine phosphatases identified to date includes MKP-1 (DUSP1), PAC-1 (DUSP2), hVH2/MKP2 (DUSP4), MKP-X (DUSP7), MKP-4 (DUSP9), MKP-5 (DUSP10), hVH5/M3/6 (DUSP8), MKP-6 (DUSP14), MKP-7 (DUSP16), and MKP-8 (DUSP26), all of which can dephosphorylate serine/threonine and tyrosine residues on different MAP kinase family members, leading to their inactivation (8, 25, 43). These phosphatases share a common structure consisting of a catalytic domain with high levels of sequence similarity to vaccinia virus dual-specificity tyrosine phosphatase (VH-1). These enzymes also contain a more divergent amino-terminal noncatalytic domain containing two short segments of sequence similarity with the Cdc25 phosphatase catalytic domain. As dual-specificity phosphatases are activated by stimuli that trigger MAP kinase pathways (such as heat shock, hypoxia, and mitogens), it has been proposed that DSPs negatively regulate MAP kinase signaling (8, 25, 29). DSPs are able to dephosphorylate one or more MAP kinases. For example, MKP-3 dephosphorylates ERK, M3/6 dephosphorylates JNK, MKP-1 dephosphorylates JNK, ERK, and p38 (16), and MKP-8 (DUSP26) was recently shown to dephosphorylate p38 (43). Numbers of DSPs (MKP-5/DUSP10, MKP-X/DUSP7, and MKP-2/DUSP4) are located in the human genome that are often found lost in tumors, suggesting that some of these phosphatases may possess tumor suppressor properties (16).
Many MAP kinases are known to bind scaffold proteins (such as JIP1-3, ß-arrestin-2, MP1, and KSR) (24, 28, 39). These scaffold proteins act to control the activity of MAP kinases and thus ultimately regulate phosphorylation of downstream MAP kinase targets. For example, ß-arrestin-2 acts as a scaffold protein which controls the activity of JNK3 and thereby desensitization of the heterotrimeric guanine nucleotide binding protein-coupled receptors (10).
Here, we show that Hsf4b binds to a dual-specificity tyrosine phosphatase similar to a group of DSPs that lack the amino-terminal CH2 domain. We also show that Hsf4b is phosphorylated by ERK1/2. Coexpression of Hsf4b with DUSP26 leads to dephosphorylation of Hsf4b as well as a reduction in its ability to bind HSEs. Hsf4b is not directly dephosphorylated by DUSP26, but Hsf4b interaction with DUSP26 brings this phosphatase into close proximity of an ERK-binding region on Hsf4b, leading to control of the activities of both ERK and Hsf4b. Therefore, DUSP26 interaction with Hsf4b places this transcription factor in a regulatory circuit within the MAP kinase signaling pathway.
| METHODS AND MATERIALS |
|---|
|
|
|---|
296 was the gift of M. Iwashima (Medical College of Georgia). The plasmid pcDNA3-Flag (NH2-terminal)-DUSP26 was constructed using DUSP26 cDNA from the plasmid pMyr-DUSP26 that was isolated from the yeast two-hybrid screening using the restriction enzymes KpnI and XhoI. The expression vector DUSP26-EGFP was constructed by insertion of PCR-amplified DUSP26 cDNA into plasmid pEGFP-N1 (Clontech) at BamHI and EcoRI restriction enzyme sites. The plasmid pcDNA3-Flag-Hsf4b was generated by inserting a Flag tag sequence at the NH2 terminus of Hsf4b cDNA followed by its insertion into pcDNA3 plasmid. The plasmids pEBG-Hsf4b (1-230), pEBG-Hsf4b (1-323), pEBG-Hsf4b (196-493), pEBG-Hsf4b (246-323), and pEBG-Hsf4b were constructed by inserting the corresponding Hsf4b cDNA fragments into the vector pEBG (gift of R. Feig, Toft University School of Medicine) using BamHI and ClaI restriction sites. The plasmid pEBG-Hsf4b allows expression of the glutathione S-transferase (GST)-Hsf4b fusion protein in mammalian cells.
Yeast two-hybrid screening.
For yeast two-hybrid screening, we used a CytoTrap two-hybrid system (Stratagene) as described previously (3, 22). The full-length human Hsf4b was subcloned into the pSos vector and was used to screen a human heart tissue cDNA library that had been subcloned into the pMyr vector. Ten micrograms of the bait construct and 10 µg of the cDNA library were cotransfected into the competent yeast Cdc25H strain. The transformed yeast were plated into SD-(uracil-leucine-deficient) glucose plates and allowed to grow at 25°C for 48 to 72 h. Yeast colonies that appeared on the plates were replica plated on SD-(uracil-leucine-deficient) galactose and SD-(uracil-leucine-deficient) glucose plates and incubated at 37°C for 6 days. Colonies positive for growth on galactose but not glucose were grown in 5 ml of SD-glucose broth at 25°C. Plasmid DNA was extracted, and transformed Escherichia coli DH5
and selected on chloramphenicol-containing agar plates. Plasmid DNA was isolated and sequenced. All control plasmids were supplied by the manufacturer and used as positive controls.
Cell culture and heat treatment. The H1299 human lung carcinoma cell line was maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum. Cultured cells were heated at 80% confluence in a circulating water bath, as appropriate.
Transient-transfection assays. Transient transfections were performed using Trans IT-Lt1 (Mirus Corporation). Transfected DNA mixes included 4 to 8 µg of expression plasmid DNA and, when required, empty plasmid DNA added to a total of 8 µg. The DNA mix was added to 5 x105 to 6 x105 cells. The transfection efficiency varied between 60 to 70% in all experiments, as determined by immunofluorescence analysis (22).
Immunoprecipitation, immunoblotting, immunocomplex kinase assays, pull-down assays.
Cells (6 x 105) were cotransfected with appropriate plasmids, allowed to recover for 48 h, rinsed with phosphate-buffered saline (PBS), and appropriately treated and harvested. Cells were lysed with lysis buffer (150 mM NaCl, 1% NP-40, 50 mM Tris, pH 7.5, containing 1x cocktail of protease inhibitors [Sigma]). The protein concentration of the supernatant was estimated using a bicinchoninic acid protein assay kit (Bio-Rad). One milligram of each of the cell lysates was mixed with 40 µl of a 50% solution of protein A-agarose and incubated at 4°C for 1 h. The protein A-agarose was then centrifuged, and the precleared supernatant was incubated with 2.5 µg of primary antibody and incubated at 4°C for 2 h or overnight. Forty microliters of 50% solution of protein A-agarose was then added at 4°C, for 2 h. The protein A complexes were centrifuged at 10,000 x g for 1 min, and the pellet was washed with lysis buffer three times. One hundred microliters of 2x sodium dodecyl sulfate (SDS) sample buffer was added, and samples were heated at 100°C for 5 min. Samples were fractionated on SDS-polyacrylamide gel electrophoresis (PAGE) and analyzed by immunoblotting using appropriate antibodies. The membrane was immunoblotted using one of the following primary antibodies as described in the text. The corresponding horseradish peroxidase-conjugated secondary antibodies were used, and signals were developed using the enhanced chemiluminescence method (ECL kit; Amersham Pharmacia) (22). For immunocomplex kinase assays, H1299 cells were treated as described in the text. Cells were then lysed in lysis buffer (25 mM Tris-HCl, pH 7.4, 15 mM NaCl, 1.5 mM MgCl2, 2 mM EGTA, 125 mM sodium phosphate, 1% Triton X-100, 10 mM NaF, 2 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride [PMSF], 2 mM sodium vanadate, and 20 µg/ml aprotinin). The protein kinases were immunoprecipitated by incubation with 2 µg of appropriate antibodies (polyclonal rabbit antibody to ERK1/2, JNK1, or p38) (Santa Cruz) as described above. Immunoprecipitated samples were rinsed twice with buffer containing 20 mM Tris-HCl, pH 7.5, 0.5 M NaCl, 1 mM PMSF, 2 mM dithiothreitol (DTT), and 1 mM sodium orthovanadate and then rinsed once with Tris buffer (Tris-HCl, pH 7.4). The beads were then mixed with 5 µg of the substrate in kinase reaction buffer (20 mM Tris-HCl, pH 7.5, 10 mM MgCl2, 100 µM ATP, 2 µCi of [
-32P]ATP) at 37°C for 15 min. The reaction was stopped by the addition of SDS sample buffer. Substrate phosphorylation was detected by autoradiography after SDS-PAGE (19).
For in vitro pull-down assays, 800 µg of cell lysate prepared in buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM MgCl2, 1% Triton X-100, 10% glycerol) following transient transfection with expression plasmids encoding Flag-Hsf4b were incubated with 20 µl of 50% slurry of glutathione-conjugated Sepharose 4b beads, and precleared supernatant was then incubated with 20 µg of purified GST-DUSP26 expressed in E. coli BL21 and incubated at 4°C for 6 h. The GST-DUSP26 proteins were precipitated with the 50 µl of a 50% slurry of glutathione-conjugated Sepharose 4b beads. After rinsing three times with lysis buffer and once in buffer containing 50 mM Tris-HCl, pH 7.4, 200 mM NaCl, beads were boiled in the SDS sample buffer. Proteins were separated via SDS-PAGE, transferred to the membrane, and immunoblotted. For in vivo pull-down assays, H1299 cells were cotransfected with expression construct pEBG-Hsf4b (1-230), pEBG-Hsf4b (1-323), pEBG-Hsf4b (196-493), or pEBG-Hsf4b (full-length) together with plasmids containing DUSP26-enhanced green fluorescent protein (EGFP) fusion protein or pcDNA3-Flag-DUSP26. Cells were lysed after 48 h in buffer (as above), and 800 µg of cell lysate was incubated with 30 µl of a 50% slurry of glutathione-conjugated Sepharose 4B beads. Beads were washed three times, and bound proteins were separated on 12% SDS-PAGE gels as described above and immunoblotted. Antibodies to Flag, hemagglutinin (HA), phospho-JNK, and GST were purchased from Sigma.
Phosphatase assay. Purified protein prepared from the construct encoding GST-DUSP26 was incubated at indicated concentrations for increasing times at 37°C in a reaction buffer containing 50 mM imidazole (pH 7.5), 20 mM p-nitrophenol phosphate (pNPP), and 5 mM dithiothreitol. The reaction was stopped by the addition of 0.1 N NaOH, and pNPP hydrolysis was measured by absorbance at 405 nm (15).
Gel mobility shift assays.
Electrophoretic mobility shift analysis (EMSA) using whole-cell extracts has been described previously (19). Briefly, after each treatment, cells were rinsed with PBS and lysed in 100 µl of extraction buffer (10 mM HEPES, pH 7.9, 0.4 mM NaCl, 0.1 mM EDTA, 0.5 mM DTT, 5% glycerol, 0.5 mM PMSF). The protein concentration of samples was estimated by the bicinchoninic acid method (Pierce). Equal amounts of protein (10 µg) in extraction buffer (volume not exceeding 15 µl) were added to the reaction mixture, which contained 4 µl of binding buffer (37.5 mM NaCl, 15 mM Tris-HCl, pH 7.4, 0.1 mM EDTA, 0.5 mM DTT, 5% glycerol), 10 µg of yeast tRNA, 1 µg of sheared E. coli DNA, 10 µg of poly(dI-dC), and 1 ng of 32P-labeled HSE oligonucleotide. The mixture was incubated for 15 min at 25°C and resolved on a 4.5% nondenaturing polyacrylamide gel. After electrophoresis, gels were fixed in 7% (vol/vol) acetic acid for 5 min, rinsed once in distilled water, dried under a vacuum, and exposed to X-ray film. The nucleotide sequence used for HSE was as follows: 5'-GTCGACGGATCCGAGCGCCTCGAATGTTCTAGAAAAGG-3'. The double-stranded oligonucleotide was labeled using Klenow fragment of DNA polymerase I, deoxynucleotide triphosphates, and [
-32P]dCTP.
Two-dimensional single amino acid analysis. H1299 cells were cotransfected with expression plasmids pcDNA3-Flag-Hsf4b and pcDNA3-HA-DUSP26. At 36 h after transfection, cells were washed twice with serum-free and phosphate-free Dulbecco's modified Eagle's medium. Cells were incubated in phosphate-free medium for 1 h prior to labeling with 200 µCi/ml of 32P for 4 h at 37°C. Cells were washed twice with PBS and lysed in NP-40 buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% NP-40, 10 mM NaF, 1 mM PMSF, 2 mM sodium vanadate, and 20 µg/ml aprotinin). The 32P-labeled Flag-Hsf4b was immunoprecipitated using antibody to Flag. The immunoprecipitated complex was then separated by SDS-PAGE, transferred to a membrane, and exposed to X-ray film to quantitate the labeled Hsf4b. The area of the membrane containing the 32P-labeled Flag-Hsf4b was excised, rinsed with methanol for 30 s and then water for 30 s, treated with 6 N HCl, and boiled at 100°C for 60 min. Samples were dried, and Cerenkov counts were determined. Samples were resuspended in 5 to 10 µl of buffer (pH 1.9) loaded onto thin-layer chromatography plates and resolved by chromatography using 1.5-kV constant voltage for 20 min in buffer containing formic acid (pH 1.9), glacial acetic acid, and deionized water (1:3:36). The plates were rinsed and resolved in buffer containing glacial acetic acid, pyridine, and deionized water (pH 3.5) (1:10:189) for 16 min. Unlabeled standard amino acids were visualized 30 min after spraying the plates with 0.25% ninhydrin in acetone at 65°C. The thin-layer chromatography plates were exposed to X-ray film and quantitated using PhosphorImager analyses (6).
| RESULTS |
|---|
|
|
|---|
|
The finding that Hsf4b binds a predicted DSP raises the possibility that Hsf4b activity may be regulated by phosphorylation. Thus, it was necessary to establish that DUSP26 possesses protein phosphatase activity and that Hsf4b exists as a phosphoprotein within cells. Hence, DUSP26 phosphatase activity was determined in vitro. The results show that GST-DUSP26 and not the mutant form of GST-DUSP26, with cysteine-to-alanine substitution at a critical residue conserved within this family of phosphatases lacked any phosphatase activity (Fig. 2A and B). The quantities of the purified GST, wild-type GST-DUSP26, and mutant GST-DUSP26 (C152A) proteins are presented in Fig. 2C. A comparative analysis in terms of DUSP26 activity per microgram of protein toward pNPP used as a substrate indicate that DUSP26 is at least as active as other DSPs such as SKRP1 (50).
|
|
We also examined whether DUSP26 has any effect on the endogenous or overexpressed Hsf4b intracellular localization by immunostaining. Endogenous or overexpressed Hsf4b expression was detected mainly in the nuclei in the absence of DUSP26-EGFP or HA-DUSP26. However, some colocalization of Hsf4b and DUSP26 was observed both in the nucleus and in the perinuclear region in 95% of the cells (data not shown).
Since Hsf4b is a transcription factor and the targets for Hsf4b exist in the nucleus, we propose that DUSP26 could potentially act to inhibit Hsf4b transcriptional ability by promoting Hsf4b cytosolic localization.
Hsf4b is phosphorylated by MAP kinases, and its phosphorylation is indirectly regulated by DUSP26. Among others, data presented in Fig. 3 suggest either that Hsf4b can be directly dephosphorylated by DUSP26 or that DUSP26 may inactivate a kinase, such as one of the MAP kinase family members which are known substrates of DSPs, and thereby reduce phosphorylation of Hsf4b by such kinases. To address these possibilities, we first tested whether in vivo-labeled 32P-Hsf4b can be dephosphorylated by immunoprecipitated DUSP26 in vitro. The quantitation of the data shown in Fig. 4 indicate a twofold reduction in the 32P-Hsf4b in cells expressing DUSP26, but the amount of Flag-Hsf4b that was immunoprecipitated was also twofold lower, indicating that DUSP26 does not directly dephosphorylate Flag-Hsf4b.
|
|
|
ERK MAP kinase and DUSP26 bind Hsf4b. DUSP26 lacks the CH2 domain, and as predicted, it does not bind ERK1/2 directly, and this was confirmed by coimmunoprecipitation experiments (see Fig. 8, below). However, since DUSP26 appears to affect ERK1/2 activity toward Hsf4b, we hypothesized that DUSP26, while bound to Hsf4b, may regulate the activity of ERK1/2. Thus, coimmunoprecipitation experiments were performed to detect the interaction between Hsf4b and ERK1/2. Results show that Hsf4b interacts with ERK1/2 in vivo (Fig. 7A). To determine the region of Hsf4b interacting with ERK1/2, in vivo-expressed full-length GST-Hsf4b or deletion mutants were used to pull down ERK1/2, which was detected by immunoblotting. The results presented in Fig. 7B indicate that full-length Hsf4b and Hsf4b residues 196 to 493 or 1 to 323 were sufficient to pull down ERK1/2. Since Hsf4b residues 1 to 230 were not required for ERK1/2 binding, we concluded that residues 196 to 493 are sufficient for ERK1/2 binding to Hsf4b. The full-length Hsf4b sequence contains three potential MAP kinase binding motifs: the first is located between amino acid residues 207KRKLSLML214 (critical amino acids are underlined); the second is between residues 285RREKGLAL292; the third is located between amino acid residues 361DRGPLGLES369. In vivo GST pull-down experiments using a mutant Hsf4b where the first MAP kinase binding motif had been disrupted by 207GRGLSLML214 indicate that interaction of ERK1/2 with Hsf4b was not affected, suggesting that this domain is not required for ERK1/2 binding to Hsf4b (data not shown). We then performed in vivo GST pull-down experiments where we used wild-type or mutated Hsf4b containing various fragments encoding MAP kinase binding region two or three, mentioned above. Our results show that ERK1 binds to Hsf4b containing amino acid residues 196 to 493 (Fig. 7C, lane 2), 323 to 371 (Fig. 7C, lane 4), and 246 to 323 (Fig. 7C, lane 6), encoding both MAP kinase binding regions. In addition, mutations of the critical amino acid residues in regions two (285GGEKGLAL292) (Fig. 7C, lane 5) and three (361DRGPAGAES369) (Fig. 7C, lane 3) lead to abolishment of binding of ERK1 to Hsf4b. These data suggest that ERK1 can bind Hsf4b in two different regions.
|
|
Thus far, we have presented evidence that ERK1 interacts with Hsf4b in two separate regions (regions two and three) and DUSP26 interacts with Hsf4b in region two (Fig. 7), and as we mentioned earlier, consistent with other DSPs that lack the CH2 domain, DUSP26 does not bind ERK1/2 directly. The question remaining was whether both ERK1 and DUSP26 interact with Hsf4b simultaneously. Thus, we performed the following experiment: cells were transiently transfected with GST-Hsf4b (amino acid residues 196 to 493) or GST alone and cotransfected with HA-ERK1 and Flag-DUSP26. Immunoprecipitation experiments were performed using antibody to Flag-DUSP26 and immunoblotted with antibody to HA-ERK1 (Fig. 8, upper left panel) and GST (Fig. 8, lower left panel). The results show that Flag-DUSP26 is in the same complex as HA-ERK1 and GST-Hsf4b (Fig. 8, upper left panel, lane 2) and not in cells expressing GST alone (Fig. 8, upper left panel, lane 1), indicating that both ERK1 and DUSP26 interact with Hsf4b simultaneously. Under the experimental conditions utilized, the interaction of GST-Hsf4b, Flag-DUSP26, and HA-ERK1 is the only likely possibility, since DUSP26 and ERK1 do not interact with each other, as shown in the immunoprecipitation group containing GST alone or the group containing only HA-ERK1 and Flag-DUSP26 (Fig. 8, upper left panel, lane 1 or 3, respectively). The right panel in Fig. 8 shows an immunoblot of the same cell lysates using antibody to HA-ERK1, Flag-DUSP26, and GST.
DUSP26 and Hsf4b express in neurons. To determine which cell types may express both Hsf4b and DUSP26, we performed PCR analyses using cDNA synthesized from several tissues obtained from adult mice. The results indicate that while Hsf4b expression was detected in the cerebellum, brain, liver, lung, and eye, DUSP26 expression could only be detected in skeletal muscle, cerebellum, and brain (Fig. 9A). Low levels of expression of DUSP26 and Hsf4b were also detected in the spleen. These results indicate that high levels of Hsf4b and DUSP26 express in the mouse brain. These results were also confirmed using immunoblotting of whole brain using antibody specific to mouse Hsf4b or DUSP26 (Fig. 9B, upper panel). The primary cultures of murine astrocytes show no DUSP26 expression but they do express Hsf4b (Fig. 9B). To determine whether endogenous Hsf4b and DUSP26 interact in vivo, we performed coimmunoprecipitation experiments using antibody to Hsf4b to pull down DUSP26 using the same cell population obtained from brain or primary astrocyte cultures (shown in Fig. 9B). The results indicate that Hsf4b and DUSP26 interact in brain cell lysates, while no interaction could be observed in the cell lysates obtained from astrocytes (Fig. 9C).
|
| DISCUSSION |
|---|
|
|
|---|
To identify Hsf4b-interacting partner proteins, we screened a human heart cDNA library using a yeast two-hybrid system and identified a dual-specificity tyrosine phosphatase (DUSP26) binding to Hsf4b. DUSP26 belongs to the low-molecular-weight (LMW) type of dual-specificity tyrosine phosphatases, since it lacks the Cdc25 homology domain thought to be required for binding to MAP kinases (25, 43). Among the DSPs identified so far, only JKAP, VHR, SKRP1, MKP6/DUSP14, and JSP1 belong to the LMW type, and their effects on MAP kinases remain controversial (25). The most direct evidence for an effect of LMW DSP on MAP kinase signaling comes from the targeted disruption of JKAP, which illustrates its role both as a positive regulator for the JNK signaling pathway and in JNK pathway activation by cytokine stimulation (9). JKAP specifically activates JNK but not p38 or ERK2. In contrast, vaccinia virus VH1-related VHR phosphatase down regulates the JNK signaling by binding and dephosphorylating JNK and also has some specificity toward ERK1 and 2 (42). Another DSP that is VH1/VHR related is the VHX phosphatase, which mainly dephosphorylates ERK2 (2). The stress-activated protein kinase pathway-regulated phosphatase 1 (SKRP1) inactivates JNK signaling and has been shown to interact with MKK7 upstream of JNK (50). DUSP26 has been recently shown to inactivate p38 protein kinase (43). However, in our study, DUSP26 appears to be specific to ERK1/2 and JNK1, since expression of DUSP26 in cells leads to inactivation of only ERK1/2 and JNK1 (Fig. 5 and data not shown). Due to the structure of DUSP26 that lacks the CH2 domain, perhaps not surprisingly, we did not observe DUSP26 binding to ERK1/2, JNK1, p38, or the ERK1/2 upstream activator Mek in vivo (Fig. 8 and data not shown). In addition, using coimmunoprecipitation studies, we find that DUSP26 specifically binds to Hsf4b and not to Hsf1 or Elk1 transcription factors (data not shown).
Interestingly, although Hsf4b expression is detected in many tissues, among the tissues tested, DUSP26 expression is limited to skeletal muscle and neurons. Immunoblotting, immunoprecipitation, immunohistochemical, and immunofluorescence analyses indicate that DUSP26 may regulate Hsf4b activity in neurons. The targeted disruption of the hsf4 gene indicates that there are abnormalities in the brain of hsf4-deficient mice, and this is under investigation in our laboratory. Additional studies are required to determine the specific signaling and regulation of Hsf4b by DUSP26 and the downstream targets of Hsf4b in neurons.
In conclusion, our data describe a novel pathway for transcription factor regulation by MAP kinase signaling and suggest that transcription factors (in this case, Hsf4b) may act as a scaffold for MAP kinases as well as their phosphatases. Thus, we hypothesize a scenario where ERK1/2 and DUSP26 bind Hsf4b in close proximity and while ERK1/2 phosphorylates Hsf4b and leads to its increased DNA binding activity, DUSP26 inactivates ERK1/2 leading to dephosphorylation of Hsf4b and a reduction in its DNA binding activity. Consistent with this hypothesis, we have found that phosphorylation of Hsf4b in cells leads to an increase in the amount of Hsf4b protein, which in turn manifests in an elevated level of Hsf4b DNA binding activity. Since previous studies indicated that accumulation of Hsf4 protein in cells is sufficient to affect transcription of downstream target genes (35, 41, 51), we suggest that the effect of ERK and DUSP26 on Hsf4b DNA binding activity is sufficient to also affect transcription. Surprisingly, stimulation of cells by sorbitol, which activates p38 (as well as JNK) MAP kinases, also leads to accumulation of Hsf4b. In contrast, treatment of cells with anisomycin, which preferentially activates JNK, did not result in an increased Hsf4b protein level. Therefore, although we could not detect an effect on p38 MAP kinase activity by DUSP26, it is conceivable that Hsf4b is phosphorylated by all three MAP kinase family members but that their effect on Hsf4b transcriptional activity could be very different and tissue specific. As far as the reason why ERK1/2 can bind in two different regions on Hsf4b and DUSP26 can only bind to one of the classical ERK1/2 binding regions, this may indicate that, in the absence of DUSP26 expression (e.g., specific tissues), ERK1/2 may bind to both regions on Hsf4b depending on its binding affinity; however, in the presence of DUSP26, only one region on Hsf4b may be available for ERK1/2 binding. More detailed analyses are required to determine the function of Hsf4b in neurons (that express both Hsf4b and DUSP26) (Fig. 9) that may require control of Hsf4b activity by MAP kinases and their phosphatases.
| ACKNOWLEDGMENTS |
|---|
This work was supported by National Institute of Health grants GM0707451 and CA62130.
| FOOTNOTES |
|---|
| REFERENCES |
|---|
|
|
|---|
2. Alonso, A., J. J. Merlo, S. Na, N. Kholod, L. Jaroszewski, A. Kharitonenkov, S. Williams, A. Godzik, J. D. Posada, and T. Mustelin. 2002. Inhibition of T cell antigen receptor signaling by VHR-related MKPX (VHX), a new dual specificity phosphatase related to VH1 related (VHR). J. Biol. Chem. 277:5524-5528.
3. Aronheim, A., E. Zandi, H. Hennenmann, S. J. Elledge, and M. Karin. 1997. Isolation of an AP-1 repressor by a novel method for detecting protein-protein interaction. Mol. Cell. Biol. 17:3094-3102.[Abstract]
4. Barford, D., A. K. Das, and M.-P. Egloff. 1998. The structure and mechanism of protein phosphatases: insights into catalysis and regulation. Annu. Rev. Biophys. Biomol. Struct. 27:133-164.[CrossRef][Medline]
5. Bharadwaj, S., A. Ali, and N. Ovsenek. 1999. Multiple components of the HSP90 chaperone complex function in regulation of HSF1 in vivo. Mol. Cell. Biol. 19:8033-8041.
6. Boyle, W. J., P. van der Geer, and T. Hunter. 1991. Phosphopeptide mapping and phosphoamino acid analysis by two dimensional separation on thin-layer cellulose plates. Methods Enzymol. 201:110-149.[Medline]
7. Bu, L., Y. Jin, Y. Shi, R. Chu, A. Ban, H. Eiberg, L. Andres, H. Jiang, G. Zheng, M. Qian, B. Cui, Y. Xia, J. Liu, L. Hu, G. Zhao, M. R. Hayden, and X. Kong. 2002. Mutant DNA-binding domain of HSF4 is associated with autosomal dominant lamellar and Marner cataract. Nat. Genet. 31:276-278.[CrossRef][Medline]
8. Camps, M., A. Nichols, and S. Arkinstall. 2000. Dual specificity phosphatases: a gene family for control of MAP kinase function. FASEB 14:6-16.
9. Chen, A. J., G. Zhou, T. Juan, S. M. Colicos, J. P. Cannon, et. al. 2002. The dual specificity JKAP specifically activates the c-Jun N-terminal kinase pathway. J. Biol. Chem. 277:36592-36601.
10. Chen, W., K. C. Kirkbride, T. How, C. D. Nelson, J. Mo, J. P. Frederick, X. F. Wang, R. J. Lefkowitz, and G. C. Blobe. 2000. Beta-arrestin 2 mediates endocytosis of type III TGF-beta receptor and down-regulation of its signaling. Science 290:1574-1577.
11. Chu, B., F. Soncin, B. D. Price, M. A. Stevenson, and S. K. Calderwood. 1996. Sequential phosphorlyation by mitogen activated protein kinase and glycogen synthase kinase-3 represses transcriptional activation by heat shock factor-1. J. Biol. Chem. 271:30847-30857.
12. Chu, B., R. Zhong, F. Soncin, M. A. Stevenson, and S. K. Calderwood. 1998. Transcriptional activity of heat shock factor 1 at 37°C is repressed through phosphorylation on two distinct serine residues by GSK-3z and PKC
and z. J. Biol. Chem. 273:18640-18646.
13. Dai, R., B. He, W. Freitag, Y. Zhang, and N. F. Mivechi. 2000. JNK targeting and phosphorylation of heat shock factor-1 suppress its transcriptional activity. J. Biol. Chem. 275:18210-18218.
14. Davis, R. J. 1993. The mitogen activated protein kinase signal transduction pathway. J. Biol. Chem. 268:14553-14556.
15. Dickinson, R. J., D. J. Williams, D. N. Slack, J. Williamson, O. M. Seternes, and S. M. Keyse. 2002. Characterization of a murine gene encoding a developmentally regulated cytoplasmic dual specificity mitogen-activated protein kinase phosphatase. Biochemical J. 364:145-155.[Medline]
16. Ducruet, A. P., A. Vogt, P. Wipf, and J. S. Lazo. 2005. Dual specificity protein phosphatases: therapeutic targets for cancer and Alzheimer's disease. Annu. Rev. Med. 45:725-750.
17. Frejtag, W., Y. Zhang, R. Dai, M. G. Anderson, and N. F. Mivechi. 2001. Heat shock factor-4 (HSF-4a) represses basal transcription through interaction with TFIIF. J. Biol. Chem. 276:14685-14694.
18. Fujimoto, M., H. Izu, K. Seki, K. Fukuda, T. Nishida, S. Yamada, K. Kato, S. Yonemura, S. Inouye, and A. Nakai. 2004. HSF4 is required for normal cell growth and differentiation during mouse lens development. EMBO J. 23:4297-4306.[CrossRef][Medline]
19. He, B., Y.-H. Meng, and N. F. Mivechi. 1998. GSK-3 and ERK MAPK inactivate HSF-1 by facilitating the disappearance of transcriptionally active granules after heat shock. Mol. Cell. Biol. 18:6624-6633.
20. Holmberg, C. I., V. Hietakangas, A. Mikhailov, J. O. Rantanen, M. Kallio, A. Meinander, J. Hellman, N. Morrice, C. Mackintosh, R. I. Morimoto, J. E. Eriksson, and L. Sistonen. 2001. Phosphorylation of serine 230 promotes inducible transcriptional activity of HSF1. EMBO J. 20:3800-3810.[CrossRef][Medline]
21. Hong, Y., and K. D. Sarge. 1999. Regulation of protein phosphatase 2A activity by heat shock transcription factor 2. J. Biol. Chem. 274:12967-12970.
22. Hu, Y., and N. F. Mivechi. 2003. HSF-1 interacts with Ral-binding protein 1 in a stress-responsive, multiprotein complex with HSP90 in vivo. J. Biol. Chem. 278:17299-17306.
23. Kallio, M., Y. Chang, M. Manuel, T. P. Alstalo, M. Rallu, Y. Gitton, L. Pirkkala, M. Y. Loones, L. Paslaru, S. Larney, S. Hirad, M. Morange, L. Sistonen, and V. Mezger. 2002. Brain abnormalities, defective meiotic chromosome synapsis and female subfertility in Hsf2 null mice. EMBO J. 21:2591-2601.[CrossRef][Medline]
24. Kelkar, N., S. Gupta, M. Dickens, and R. J. Davis. 2000. Interaction of a mitogen-activated protein kinase signaling module with the neuronal protein JIP3. Mol. Cell. Biol. 20:1030-1043.
25. Keyse, S. M. 2000. Protein phosphatases and the regulation of mitogen-activated protein kinase signaling. Curr. Opin. Cell Biol. 12:186-192.[CrossRef][Medline]
26. Kim, J., A. Nueda, Y-H. Meng, W. S. Dynan, and N. F. Mivechi. 1997. Analysis of the phosphorylation of human heat shock transcription factor-1 by MAP kinase family members. J. Cell. Biochem. 67:43-54.[CrossRef][Medline]
27. Kline, M. P., and R. I. Morimoto. 1997. Repression of the heat shock factor 1 transcriptional activation domain is modulated by constitutive phosphorylation. Mol. Cell. Biol. 17:2107-2115.[Abstract]
28. Kortum, R. L., and R. E. Lewis. 2004. The molecular scaffold KSR1 regulates the proliferative and oncogenic potential of cells. Mol. Cell. Biol. 24:4407-4416.
29. Mandl, M., D. N. Slack, and S. M. Keyse. 2005. Specific interaction and nuclear anchoring of extracellular signal-regulated kinase 2 by the inducible dual specificity protein phosphatases DUSP5. Mol. Cell. Biol. 25:1830-1845.
30. Mathew, A., S. K. Mathur, and R. I. Morimoto. 1998. Heat shock response and protein degradation: regulation of HSF2 by the ubiquitin-proteosome pathway. Mol. Cell. Biol. 18:5091-5098.
31. McMillan, D. R., E. Christians, M. Forster, X.-Z. Xiao, P. Connell, J.-C. Plumier, X. Zuo, J. Richardson, S. Morgan, and I. J. Benjamin. 2002. Heat shock transcription factor 2 is not essential for embryonic development, fertility, or adult cognitive and psychomotor function in mice. Mol. Cell. Biol. 22:8005-8014.
32. McMillan, D. R., X. Xiao, L. Shao, K. Graves, and I. J. Benjamin. 1998. Targeted disruption of heat shock transcription factor 1 abolishes thermotolerance and protection against heat-inducible apoptosis. J. Biol. Chem. 273:7523-7528.
33. Min, J.-N., Y. Zhang, D. Moskophidis, and N. F. Mivechi. 2004. Unique contribution of Hsf4 in ocular lens development and fiber cell differentiation. Genesis 40:205-217, 2004.[CrossRef][Medline]
34. Morimoto, R. I. 1998. Regulation of the heat shock transcriptional response: cross talk between a family of heat shock factors, molecular chaperones, and negative regulators. Genes Dev. 12:3788-3796.
35. Nakai, A., M. Tanabe, Y. Kawazoe, J. Inazawa, R. I. Morimoto, and K. Nagata. 1997. HSF-4, a new member of the human heat shock factor family which lacks properties of a transcriptional activator. Mol. Cell. Biol. 17:469-481.[Abstract]
36. Rallu, M., M. Loones, Y. Lallemand, R. Morimoto, M. Morange, and V. Mezger. 1997. Function and regulation of HSF2 during mouse embryogenesis. Proc. Natl. Acad. Sci. USA 94:2392-2397.
37. Sarge, K. D., K. Park-Sarge, J. D. Kirby, K. E. Mayo, and R. I. Morimoto. 1994. Expression of heat shock factor 2 in mouse testis: potential role as a regulator of heat shock protein gene expression during spermatogenesis. Biol. Reprod. 50:1392-1407.
38. Satyal, S. H., D. Chen, S. G. Fox, J. M. Kramer, and R. I. Morimoto. 1998. Negative regulation of the heat shock transcriptional response by HSBP1. Genes Dev. 12:1962-1974.
39. Schaeffer, H. J., A. D. Catling, S. T. Eblen, L. S. Collier, A. Krauss, and M. J. Weber. 1998. MP1: a MEK binding partner that enhances enzymatic activation of the MAP kinase cascade. Science 281:1668-1671.
40. Shinka, T., Y. Sato, G. Chen, T. Naroda, K. Kinoshita, Y. Unemi, K. Tsuji, T. Iwamoto, and Y. Nakahori. 2004. Molecular characterization of heat shock-like factor encoded on the human chromosome, and implications for male infertility. Biol. Reprod. 71:297-306.
41. Tanabe, M., N. Sasai, K. Nagata, X.-D. Liu, P. C. C. Liu, D. J. Thiele, and A. Nakai. 1999. The mammalian HSF-4 gene generates both an activator and a repressor of heat shock genes by alternative splicing. J. Biol. Chem. 274:27845-27856.
42. Todd, J. L., J. D. Rigas, L. A. Rafty, and J. M. Denu. 2002. Dual-specificity protein tyrosine phosphatase VHR down-regulates c-Jun N-terminal kinase (JNK). Oncogene 21:2573-2583.[CrossRef][Medline]
43. Vasudevan, S. A., J. Skoko, K. Wang, S. M. Burlingame, P. N. Patel, J. S. Lazo, J. G. Nuchtern, and J. Yang. 2005. MKP-8, a novel MAPK phosphatase that inhibits p38 kinase. Biochem. Biophys. Res. Commun. 330:511-518.[CrossRef][Medline]
44. Wang, G., Z. Ying, X. Jin, N. Tu, Y. Zhang, M. Phillips, D. Moskophidis, and N. F. Mivechi. 2004. Essential requirement for both hsf1 and hsf2 transcriptional activity in spermatogenesis and male fertility. Genesis 38:66-80.[CrossRef][Medline]
45. Wang, G., J. Zhang, D. Moskophidis, and N. F. Mivechi. 2003. Targeted disruption of the Hsf2 gene results in increased embryonic lethality, neuronal defects, and reduced spermatogenesis. Genesis 36:48-61.[CrossRef][Medline]
46. Wang, X., N. Grammatikakis, A. Siganou, and S. K. Calderwood. 2003. Regulation of molecular chaperone gene transcription involves the serine phosphorylation, 14-3-3e binding, and cytoplasmic sequestration of heat shock factor 1. Mol. Cell. Biol. 23:6013-6026.
47. Wu, C. 1995. Heat shock transcription factors: structure and regulation. Annu. Rev. Cell Dev. Biol. 11:441-469.[CrossRef][Medline]
48. Xia, W., Y. Guo, N. Vilaboa, J. Zuo, and R. Voellmy. 1998. Transcriptional activation of heat shock factor HSF-1 probed by phosphopeptide analysis of factor 32P-labeled in vivo. J. Biol. Chem. 273:8749-8755.
49. Xiao, X., X. Zuo, A. A. Davis, D. R. McMillan, B. B. Curry, J. A. Richardson, and I. J. Benjamin. 1999. HSF1 is required for extra-embryonic development, postnatal growth and protection during inflammatory responses in mice. EMBO J. 18:5943-5952.[CrossRef][Medline]
50. Zama, T., R. Aoki, T. Kamimoto, K. Inoue, Y. Ikeda, and M. Hagiwara. 2002. A novel dual specificity phosphatase SKRP1 interacts with the MAPK kinase MKK7 and inactivates the JNK MAPK pathway. Implication for the precise regulation of the particular MAPK pathway. J. Biol. Chem. 277:23909-23918.